Company Executives

$SNTI Management Team

Dr. Timothy Lu

Chief Executive Officer

Director

Age 44

Compensation $1.373M USD

Sex Male

Mr. Jay Cross

Chief Financial Officer

Principal Accounting Officer

Principal Financial Officer

Age 54

Compensation -

Sex Male

Dr. Kanya Rajangam

President

Head - Research and Development

Chief Medical Officer

Age 51

Compensation $893.2K USD

Sex Female

Name / Title	Age	Compensation	Sex
Dr. Timothy Lu Chief Executive Officer Director	44	$1.373M USD	Male
Mr. Jay Cross Chief Financial Officer Principal Accounting Officer Principal Financial Officer	54	-	Male
Dr. Kanya Rajangam President Head - Research and Development Chief Medical Officer	51	$893.2K USD	Female

Board of Directors

From the proxy statement filed Apr 30, 2025

Directors

serving now

Independent

5 of 5

stated in the proxy; 2 not stated

Average tenure

4.1 years

from year joined

CEO also chairs the board

Not stated

no chair stated

Director	Age	On board	Independent	Committees	Other public boards	2024 pay
Brenda Cooperstone	59	2019 6 years	Independent	Compensation Committee · Chair	Lexeo Therapeutics, Inc. (NASDAQ: LXEO)	$64,849
James (Jim) Collins	58	2022 3 years	Independent	Nominating and Corporate Governance Committee	None stated	Not stated
Feng Hsiung	50	2025 0 years	Independent	Audit Committee	None stated	Not stated
Timothy Lu CEO	44	2016 9 years	Not stated	None stated	None stated	Paid as CEO
Edward Mathers	65	2016 9 years	Independent	Audit Committee	Inozyme Pharma, Inc. (NASDAQ: INZY)	$71,530
Frances D. Schulz	61	2024 1 year	Independent	Audit Committee · Chair	EDAP TMS SA (Nasdaq: EDAP)	$64,610
Donald Tang	42	2024 1 year	Not stated	None stated	None stated	$64,141

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

Related-party transactions not read yet

The latest proxy was filed Sep 24, 2026 and its related-party section is being read. Check back shortly.

Open the proxy

Comments